更新指南发布后，佐治亚州亚特兰大市社区获得性艰难梭菌感染治疗的变化，2018 年。
Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018.
机构信息
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Program, Atlanta, GA, USA.
Georgia Emerging Infections Program, Atlanta, GA, USA; Atlanta VA Medical Center, Decatur, GA, USA; Foundation for Atlanta Veterans Education and Research, Decatur, GA, USA.
出版信息
Anaerobe. 2021 Aug;70:102364. doi: 10.1016/j.anaerobe.2021.102364. Epub 2021 Apr 14.
Abstract
Updated Clostridioides difficile infection (CDI) guidelines published in 2018 recommend vancomycin as first-line treatment. Of 833 community-onset CDI cases in metropolitan Atlanta, Georgia in 2018, over half did not receive first-line treatment, although guideline adherence increased over the year. Second-line treatment was more common in patients treated in ambulatory settings.
摘要
2018 年发布的更新版艰难梭菌感染（CDI）指南建议使用万古霉素作为一线治疗药物。在 2018 年佐治亚州亚特兰大市区的 833 例社区获得性 CDI 病例中，超过一半未接受一线治疗，尽管该年度的指南遵循率有所上升。在门诊环境中接受治疗的患者更常采用二线治疗。
相似文献
1
Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018.更新指南发布后，佐治亚州亚特兰大市社区获得性艰难梭菌感染治疗的变化，2018 年。
Anaerobe. 2021 Aug;70:102364. doi: 10.1016/j.anaerobe.2021.102364. Epub 2021 Apr 14.
2
Epidemiology and factors associated with candidaemia following Clostridium difficile infection in adults within metropolitan Atlanta, 2009-2013.2009 - 2013年亚特兰大大都市地区成人艰难梭菌感染后念珠菌血症的流行病学及相关因素
Epidemiol Infect. 2016 May;144(7):1440-4. doi: 10.1017/S0950268815003027. Epub 2015 Nov 26.
3
Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.与最近的指南建议去除甲硝唑治疗非严重艰难梭菌感染相关的结果：一项回顾性、观察性、全国性队列研究。
Int J Antimicrob Agents. 2021 Mar;57(3):106282. doi: 10.1016/j.ijantimicag.2021.106282. Epub 2021 Jan 17.
4
Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?静脉注射甲硝唑是否能改善艰难梭菌感染的疗效？
Clin Infect Dis. 2020 Dec 3;71(9):2414-2420. doi: 10.1093/cid/ciz1115.
5
Comparative effectiveness of vancomycin and metronidazole on event-free survival after initial infection in patients with Clostridioides difficile-a German multicentre cohort study.万古霉素和甲硝唑对艰难梭菌初次感染后无事件生存的疗效比较：一项德国多中心队列研究。
Clin Microbiol Infect. 2024 Nov;30(11):1433-1438. doi: 10.1016/j.cmi.2024.08.003. Epub 2024 Aug 8.
6
Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality.不遵守美国医疗保健流行病学学会（SHEA）和美国感染病学会（IDSA）关于艰难梭菌感染的治疗指南与死亡率增加相关。
J Antimicrob Chemother. 2017 Feb;72(2):574-581. doi: 10.1093/jac/dkw423. Epub 2016 Nov 14.
7
Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. fidaxomicin 与甲硝唑、万古霉素及其联合治疗首发、首次复发和严重艰难梭菌感染的疗效比较：一项观察性队列研究。
Int J Infect Dis. 2021 Feb;103:226-233. doi: 10.1016/j.ijid.2020.11.004. Epub 2020 Nov 11.
8
Clinical Efficacy of Therapeutic Agents for Clostridioides difficile Infection Based on Four Severity Classifications.基于四种严重程度分类的艰难梭菌感染治疗药物的临床疗效。
Jpn J Infect Dis. 2024 Sep 19;77(5):281-284. doi: 10.7883/yoken.JJID.2023.483. Epub 2024 Mar 29.
9
Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.定义口服万古霉素或甲硝唑治疗艰难梭菌感染后艰难梭菌定植再建立的脆弱期。
PLoS One. 2013 Oct 2;8(10):e76269. doi: 10.1371/journal.pone.0076269. eCollection 2013.
10
Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.利奈唑胺：一种新型、窄谱抗菌药物，针对艰难梭菌（梭状芽孢杆菌属）。
Lett Appl Microbiol. 2022 Sep;75(3):526-536. doi: 10.1111/lam.13664. Epub 2022 Feb 11.
引用本文的文献
1
Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study.亚洲炎症性肠病患者机会性感染的现状：一项基于问卷的多中心研究。
Gut Liver. 2022 Sep 15;16(5):726-735. doi: 10.5009/gnl210217. Epub 2022 May 25.
2
Evaluation of fidaxomicin use in community hospitals after a clinical guideline change at a large health system and opportunities for stewardship.在大型医疗系统临床指南改变后，评价社区医院使用非达霉素的情况及（医院）管理的机会。
Infect Control Hosp Epidemiol. 2023 Feb;44(2):312-314. doi: 10.1017/ice.2021.456. Epub 2022 Jan 24.
3
Infection among Cirrhotic Patients with Variceal Bleeding.肝硬化静脉曲张出血患者的感染
Antibiotics (Basel). 2021 Jun 17;10(6):731. doi: 10.3390/antibiotics10060731.
本文引用的文献
1
Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.与最近的指南建议去除甲硝唑治疗非严重艰难梭菌感染相关的结果：一项回顾性、观察性、全国性队列研究。
Int J Antimicrob Agents. 2021 Mar;57(3):106282. doi: 10.1016/j.ijantimicag.2021.106282. Epub 2021 Jan 17.
2
Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of Clostridium difficile Infections in the United States.修订版美国传染病学会和美国医疗保健流行病学学会临床实践指南对美国艰难梭菌感染治疗的影响。
Clin Infect Dis. 2021 Jun 1;72(11):1944-1949. doi: 10.1093/cid/ciaa484.
3
Trends in U.S. Burden of Infection and Outcomes.美国感染负担和结局的趋势。
N Engl J Med. 2020 Apr 2;382(14):1320-1330. doi: 10.1056/NEJMoa1910215.
4
Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States.美国肺癌患者接受指南一致治疗的差异。
Ann Am Thorac Soc. 2020 Feb;17(2):186-194. doi: 10.1513/AnnalsATS.201901-094OC.
5
Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals.美国医院中与医疗保健相关的感染的患病率变化。
N Engl J Med. 2018 Nov 1;379(18):1732-1744. doi: 10.1056/NEJMoa1801550.
6
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).临床实践指南：成人和儿童艰难梭菌感染：美国传染病学会（IDSA）和美国医疗保健流行病学学会（SHEA） 2017 年更新。
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. doi: 10.1093/cid/cix1085.
7
Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.万古霉素与甲硝唑预防艰难梭菌感染患者复发和死亡的疗效比较。
JAMA Intern Med. 2017 Apr 1;177(4):546-553. doi: 10.1001/jamainternmed.2016.9045.
8
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.万古霉素、甲硝唑或托利美胺治疗艰难梭菌感染：两项多中心、随机、对照试验的结果。
Clin Infect Dis. 2014 Aug 1;59(3):345-54. doi: 10.1093/cid/ciu313. Epub 2014 May 5.
9
Achievement of guideline-concordant care and in-hospital outcomes in patients with coronary artery disease in teaching and nonteaching hospitals: results from the Get With The Guidelines-Coronary Artery Disease program.教学医院和非教学医院中冠心病患者遵循指南治疗的达成情况及院内结局：来自“遵循冠心病指南”项目的结果
Circ Cardiovasc Qual Outcomes. 2013 Jan 1;6(1):58-65. doi: 10.1161/CIRCOUTCOMES.112.965525. Epub 2012 Dec 11.
10
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).艰难梭菌感染临床实践指南：美国医疗保健流行病学学会（SHEA）和美国传染病学会（IDSA）2010 年更新版。
Infect Control Hosp Epidemiol. 2010 May;31(5):431-55. doi: 10.1086/651706.
Zotero 插件